'I want to be a granddad': Why John Maraganore left and where he (and Alnylam) are going

Jason Mast

Editor

John Maraganore knew that people would be surprised when Alnylam announced his departure this morning after 19 years as CEO of the company. But he said it shouldn’t come as too much of a shock.

“Nineteen years as a CEO leading Alnylam has been the greatest joy of my life, but 19 years has been a long time,” he said in an interview Thursday morning. That’s “being in the 24/7 operational mode of running a company for 19 years.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

'I want to be a granddad': Why John Maraganore left and where he (and Alnylam) are going

Jason Mast

Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

'I want to be a grand­dad': Why John Maraganore left and where he (and Al­ny­lam) are go­ing

Jason Mast

Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

'I want to be a granddad': Why John Maraganore left and where he (and Alnylam) are going

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa